Abstract
Aim: to assess the effectiveness and tolerability of anti-VEGF agents, aflibercept (2.0 mg) and ranibizumab (0.5 mg), in the combined treat-ment for wet age-related macular degeneration (AMD) in routine clinical practice.Patients and Methods: 55 patients (65 eyes) with the late stage of wet AMD were divided into two groups. Group 1 included 32 eyes with classic choroidal neovascularization (CNV) and group 2 included 33 eyes with occult CNV. Best-corrected visual acuity (BCVA), intraocular pressure, and retinal nerve fiber layer (RNFL) thickness were measured. These parameters were compared at different time points during the treatment.Results: overall AMD duration (January 2019) was 36 (19; 47) months being 30 (12; 44) months in group 1 and 36 (23; 48) months in group 2 (р>0.05). The first intravitreal administration of an anti-VEGF drug was performed 7.5 (3.5; 9.5) months after AMD diagnosis in group 1 and 7 (3; 11) months after AMD diagnosis in group 2. Significant differences in intragroup intervals were revealed between various follow-up periods. More differences were identified for the intervals between intravitreal administrations in group 2. Baseline and final BCVA during the entire follow-up which was 29.5 (19.5; 38) months in group 1 and 28 (25; 44) months in group 2 demonstrated neither intragroup nor intergroup differences (р>0.05). Conclusion: our management strategy for wet AMD is somewhat different from conventional guidelines. However, it has no significant impact on visual acuity during the follow-up.Keywords: age-related macular degeneration, anti-VEGF drugs, intravitreal administration, IOP level, aflibercept, ranibizumab.For citation: Kuroyedov A.V., Gapon’ko O.V., Gorodnichiy V.V. et al. Effectiveness and tolerability of the combined use of anti-VEGF agents in clinical practice. Russian Journal of Clinical Ophthalmology. 2020;20(4):209–215. DOI: 10.32364/2311-7729-2020-20-4-209-215.
Highlights
Aim: to assess the effectiveness and tolerability of anti-VEGF agents, aflibercept (2.0 mg) and ranibizumab (0.5 mg), in the combined treatment for wet age-related macular degeneration (AMD) in routine clinical practice
Conclusion: our management strategy for wet AMD is somewhat different from conventional guidelines
It has no significant impact on visual acuity during the follow-up
Summary
Цель исследования: определить эффективность и переносимость ингибиторов ангиогенеза (ИАГ) афлиберцепта (2,0 мг) и ранибизумаба (0,5 мг) при комбинированном применении в лечении пациентов с «влажной» формой возрастной макулярной дегенерации (ВМД) в условиях рутинной клинической практики. Материал и методы: были включены результаты обследования 55 пациентов (65 глаз) с поздней стадией «влажной» формы ВМД, разделенных на 2 группы. (дата начала исследования) для всех пациентов составила 36 (19; 47) мес., для 1-й группы эти значения составили 30 (12; 44) мес., во 2-й группе продолжительность заболевания была 36 (23; 48) мес. Установлено, что первое интравитреальное введение ИАГ было выполнено через 7,5 (3,5; 9,5) мес. От момента постановки диагноза ВМД в 1-й группе и через 7 (3;11) мес. Для 1-й группы и 28 (25; 44) мес. Для цитирования: Куроедов А.В., Гапонько О.В., Городничий В.В. Mandryka Military Clinical Hospital, Moscow, Russian Federation 2Pirogov Russian National Research Medical University, Moscow, Russian Federation
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
